To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
PolyMedix Appoints Vice President of Drug Development
PolyMedix, Inc. has announced that it has appointed Timothy Henkel, M.D., Ph.D. as Vice President, Drug Development and Chief Medical Officer.
Dr. Henkel has developed a number of antibiotic and antifungal drugs. He comes to PolyMedix from Vicuron Pharmaceuticals, where from 2001 to 2005 he was Executive Vice President and Chief Medical Officer.
At Vicuron he filed the NDA submissions for the antibiotic drug dalbavancin and the antifungal drug anidulafungin.
Earlier this year Pfizer made an offer to acquire Vicuron for $2 billion. Previously he was Vice President of Worldwide Anti-infective Clinical Development at GlaxoSmithKline.
He earned his M.D. and Ph.D. degrees from the Washington University School of Medicine in St. Louis.
Dr. Henkel will be leading all of PolyMedix's clinical, regulatory, and other drug development efforts.
“PolyMedix is very fortunate to have such an outstanding and experienced executive join us to lead our drug development efforts,” commented Nick Landekic, President & CEO of PolyMedix.
“We hope to advance a number of infectious disease and other compounds into clinical development in coming years. We all look forward to working with Tim as he leads these development activities.”
